nach oben

Der Nervenarzt

Erschienen in:

26.03.2021 | Krankheiten des peripheren Nervensystems | Leitthema

Neuromuskuläre Komplikationen einer SARS-CoV-2-Infektion – Teil 1: periphere Nerven

verfasst von: Prof. Dr. Helmar C. Lehmann, Benedikt Schoser, Gilbert Wunderlich, Peter Berlit, Gereon R. Fink

Erschienen in: Der Nervenarzt | Ausgabe 6/2021

Einloggen, um Zugang zu erhalten

Zusammenfassung

In den letzten Monaten sind im Zusammenhang mit einer durch das „severe acute respiratory syndrome coronavirus 2“ (SARS-CoV-2) ausgelösten Lungenerkrankung COVID-19 („coronavirus disease 2019“) verschiedene Störungen und Erkrankungen der peripheren Nerven (einschließlich Hirnnerven) und der Muskulatur beschrieben worden. Im ersten Teil unserer Übersicht diskutieren wir den aktuellen Stand einer möglichen Assoziation einer SARS-CoV-2-Infektion mit Affektionen peripherer Nerven (inklusive Hirnnerven). So wurden u. a. eine Anosmie und Ageusie, motorische Hirnnervenbeteiligung und Guillain-Barré-Syndrome (GBS) in zeitlichem Zusammenhang mit einer SARS-CoV-2-Infektion beschrieben. Mehrere Studien konnten zeigen, dass Anosmie und Ageusie häufige Symptome einer SARS-CoV-2-Infektion sind. Im Gegensatz dazu sind andere Hirnnervenausfälle bisher nur vereinzelt beschrieben worden. Eine Reihe von Fallberichten und Fallserien legt einen kausalen Zusammenhang zwischen einer SARS-CoV-2-Infektion und GBS nahe, epidemiologische Evidenz hierfür ist aber ausstehend.

Amer MA, Elsherif HS, Abdel-Hamid AS, Elzayat S (2020) Early recovery patterns of olfactory disorders in COVID-19 patients; a clinical cohort study. Am J Otolaryngol 41:102725. https://doi.org/10.1016/j.amjoto.2020.102725CrossRefPubMedPubMedCentral

Aoyagi Y, Ohashi M, Funahashi R, Otaka Y, Saitoh E (2020) Oropharyngeal Dysphagia and Aspiration Pneumonia Following Coronavirus Disease 2019: A Case Report. Dysphagia 35(4):545–548CrossRefPubMedPubMedCentral

Belghmaidi S, Nassih H, Boutgayout S et al (2020) Third cranial nerve palsy presenting with unilateral diplopia and strabismus in a 24-year-old woman with COVID-19. Am J Case Rep 21:e925897. https://doi.org/10.12659/AJCR.925897CrossRefPubMedPubMedCentral

Brito Ferreira ML, de Militão de Albuquerque MFP, Brito CAA et al (2020) Neurological disease in adults with Zika and chikungunya virus infection in Northeast Brazil: a prospective observational study. Lancet Neurol 19:826–839. https://doi.org/10.1016/S1474-4422(20)30232-5CrossRefPubMedPubMedCentral

Chiu A, Fischbein N, Wintermark M et al (2020) COVID-19-induced anosmia associated with olfactory bulb atrophy. Neuroradiology. https://doi.org/10.1007/s00234-020-02554-1CrossRefPubMedPubMedCentral

Cummings MJ, Baldwin MR, Abrams D et al (2020) Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study. Lancet 395:1763–1770. https://doi.org/10.1016/S0140-6736(20)31189-2CrossRefPubMedPubMedCentral

D’Ascanio L, Pandolfini M, Cingolani C et al (2020) Olfactory dysfunction in COVID-19 patients: prevalence and prognosis for recovering sense of smell. Otolaryngol Head Neck Surg. https://doi.org/10.1177/0194599820943530CrossRefPubMed

Defabio AC, Scott TR, Stenberg RT, Simon EL (2020) Guillain-Barré syndrome in a patient previously diagnosed with COVID-19. Am J Emerg Med. https://doi.org/10.1016/j.ajem.2020.07.074CrossRefPubMedPubMedCentral

Dhont S, Callens R, Stevens D et al (2020) Myotonic dystrophy type 1 as a major risk factor for severe COVID-19? Acta Neurol Belg. https://doi.org/10.1007/s13760-020-01514-zCrossRefPubMedPubMedCentral

10.

Diez-Porras L, Vergés E, Gil F et al (2020) Guillain-Barré-Strohl syndrome and COVID-19: Case report and literature review. Neuromuscul Disord 30:859–861. https://doi.org/10.1016/j.nmd.2020.08.354CrossRefPubMedPubMedCentral

11.

Dinkin M, Gao V, Kahan J et al (2020) COVID-19 presenting with ophthalmoparesis from cranial nerve palsy. Neurology 95:221–223. https://doi.org/10.1212/WNL.0000000000009700CrossRefPubMed

12.

Ellul MA, Benjamin L, Singh B et al (2020) Neurological associations of COVID-19. Lancet Neurol 19:767–783. https://doi.org/10.1016/S1474-4422(20)30221-0CrossRefPubMedPubMedCentral

13.

Falcone MM, Rong AJ, Salazar H et al (2020) Acute abducens nerve palsy in a patient with the novel coronavirus disease (COVID-19). J AAPOS. https://doi.org/10.1016/j.jaapos.2020.06.001CrossRefPubMedPubMedCentral

14.

Filosto M, Cotti Piccinelli S, Gazzina S et al (2020) Guillain-Barré syndrome and COVID-19: an observational multicentre study from two Italian hotspot regions. J Neurol Neurosurg Psychiatry. https://doi.org/10.1136/jnnp-2020-324837CrossRefPubMed

15.

Fitzpatrick JC, Comstock JM, Longmuir RA et al (2020) Cranial Nerve III Palsy in the setting of COVID 19 Infection. J Neuroophthalmol. https://doi.org/10.1097/WNO.0000000000001160CrossRef

16.

Giacomelli A, Pezzati L, Conti F et al (2020) Self-reported olfactory and taste disorders in patients with severe acute respiratory Coronavirus 2 infection: a cross-sectional study. Clin Infect Dis 71:889–890. https://doi.org/10.1093/cid/ciaa330CrossRefPubMed

17.

Homma Y, Watanabe M, Inoue K, Moritaka T (2020) Coronavirus disease-19 pneumonia with facial nerve palsy and olfactory disturbance. Intern Med 59:1773–1775. https://doi.org/10.2169/internalmedicine.5014-20CrossRefPubMedPubMedCentral

18.

Huang C, Wang Y, Li X et al (2020) Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395:497–506. https://doi.org/10.1016/S0140-6736(20)30183-5CrossRefPubMedPubMedCentral

19.

Kang J‑H, Sheu J‑J, Lin H‑C (2010) Increased risk of Guillain-Barré Syndrome following recent herpes zoster: a population-based study across Taiwan. Clin Infect Dis 51:525–530. https://doi.org/10.1086/655136CrossRefPubMed

20.

Keddie S, Pakpoor J, Mousele C et al (2020) Epidemiological and cohort study finds no association between COVID-19 and Guillain-Barré syndrome. Brain. https://doi.org/10.1093/brain/awaa433CrossRefPubMedPubMedCentral

21.

Khaja M, Gomez GPR, Santana Y et al (2020) A 44-year-old hispanic man with loss of taste and bilateral facial weakness diagnosed with Guillain-Barré syndrome and Bell’s palsy associated with SARS-coV‑2 infection treated with intravenous immunoglobulin. Am J Case Rep 21:e927956. https://doi.org/10.12659/AJCR.927956CrossRefPubMedPubMedCentral

22.

Kluge S, Janssens U, Spinner CD, Pfeifer M, Marx G, Karagiannidis C; Guideline group (2021) Clinical Practice Guideline: Recommendations on Inpatient Treatment of Patients with COVID-19. Dtsch Arztebl Int. https://doi.org/10.3238/arztebl.m2021.0110. Epub ahead of print. PMID: 33531113CrossRefPubMedPubMedCentral

23.

Koc G, Odabasi Z, Tan E (2020) Myasthenic syndrome caused by hydroxychloroquine used for COVID-19 prophylaxis. J Clin Neuromuscul Dis 22:60–62. https://doi.org/10.1097/CND.0000000000000316CrossRefPubMed

24.

Laurendon T, Radulesco T, Mugnier J et al (2020) Bilateral transient olfactory bulb edema during COVID-19-related anosmia. Neurology 95:224–225. https://doi.org/10.1212/WNL.0000000000009850CrossRefPubMed

25.

Lechien JR, Chiesa-Estomba CM, De Siati DR et al (2020) Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study. Eur Arch Otorhinolaryngol 277:2251–2261. https://doi.org/10.1007/s00405-020-05965-1CrossRefPubMedPubMedCentral

26.

Lehmann HC, Burke D, Kuwabara S (2019) Chronic inflammatory demyelinating polyneuropathy: update on diagnosis, immunopathogenesis and treatment. J Neurol Neurosurg Psychiatry 90:981–987. https://doi.org/10.1136/jnnp-2019-320314CrossRefPubMed

27.

Lehmann HC, Hartung H‑P (2010) Varicella-zoster virus: another trigger of Guillain-Barré syndrome? Clin Infect Dis 51:531–533. https://doi.org/10.1086/655137CrossRefPubMed

28.

Lehmann HC, Hartung H‑P, Kieseier BC, Hughes RAC (2010) Guillain-Barré syndrome after exposure to influenza virus. Lancet Infect Dis 10:643–651. https://doi.org/10.1016/S1473-3099(10)70140-7CrossRefPubMed

29.

Lehmann HC, Hughes RAC, Kieseier BC, Hartung H‑P (2012) Recent developments and future directions in Guillain-Barré syndrome. J Peripher Nerv Syst 17(Suppl 3):57–70. https://doi.org/10.1111/j.1529-8027.2012.00433.xCrossRefPubMed

30.

Liberatore G, De Santis T, Doneddu PE, Gentile F, Albanese A, Nobile-Orazio E (2020) Clinical Reasoning: A case of COVID-19–associated pharyngeal-cervical-brachial variant of Guillain-Barré syndrome. Neurology 95(21):978–983CrossRefPubMed

31.

Luers JC, Rokohl AC, Loreck N et al (2020) Olfactory and gustatory dysfunction in Coronavirus disease 19 (COVID-19). Clin Infect Dis. https://doi.org/10.1093/cid/ciaa525CrossRefPubMed

32.

Lv H, Zhang W, Zhu Z et al (2020) Prevalence and recovery time of olfactory and gustatory dysfunction in hospitalized patients with COVID-19 in Wuhan, China. Int J Infect Dis 100:507–512. https://doi.org/10.1016/j.ijid.2020.09.039CrossRefPubMedPubMedCentral

33.

Matschke J, Lütgehetmann M, Hagel C et al (2020) Neuropathology of patients with COVID-19 in Germany: a post-mortem case series. Lancet Neurol 19:919–929. https://doi.org/10.1016/S1474-4422(20)30308-2CrossRefPubMedPubMedCentral

34.

Mehraeen E, Behnezhad F, Salehi MA et al (2020) Olfactory and gustatory dysfunctions due to the coronavirus disease (COVID-19): a review of current evidence. Eur Arch Otorhinolaryngol. https://doi.org/10.1007/s00405-020-06120-6CrossRefPubMedPubMedCentral

35.

Nanda S, Handa R, Prasad A et al (2020) Covid-19 associated Guillain-Barre Syndrome: contrasting tale of four patients from a tertiary care centre in India. Am J Emerg Med. https://doi.org/10.1016/j.ajem.2020.09.029CrossRefPubMedPubMedCentral

36.

Pan S, Chen WC, Baal JD, Sugrue LP (2020) Neuroradiological features of mild and severe SARS-coV‑2 infection. Acad Radiol 27:1507–1514. https://doi.org/10.1016/j.acra.2020.08.026CrossRefPubMedPubMedCentral

37.

Paterson RW, Brown RL, Benjamin L et al (2020) The emerging spectrum of COVID-19 neurology: clinical, radiological and laboratory findings. Brain 143:3104–3120. https://doi.org/10.1093/brain/awaa240CrossRefPubMedPubMedCentral

38.

Radmard S, Epstein SE, Roeder HJ et al (2020) Inpatient neurology consultations during the onset of the SARS-coV‑2 New York city pandemic: a single center case series. Front Neurol 11:805. https://doi.org/10.3389/fneur.2020.00805CrossRefPubMedPubMedCentral

39.

Rein N, Haham N, Orenbuch-Harroch E et al (2020) Description of 3 patients with myasthenia gravis and COVID-19. J Neurol Sci 417:117053. https://doi.org/10.1016/j.jns.2020.117053CrossRefPubMedPubMedCentral

40.

Rifino N, Censori B, Agazzi E et al (2020) Neurologic manifestations in 1760 COVID-19 patients admitted to Papa Giovanni XXIII Hospital, Bergamo, Italy. J Neurol. https://doi.org/10.1007/s00415-020-10251-5CrossRefPubMedPubMedCentral

41.

Schmidt J (2018) Current classification and management of inflammatory myopathies. J Neuromuscul Dis 5:109–129. https://doi.org/10.3233/JND-180308CrossRefPubMedPubMedCentral

42.

Schneider C, Wunderlich G, Bleistein J et al (2017) Lymphocyte antigens targetable by monoclonal antibodies in non-systemic vasculitic neuropathy. J Neurol Neurosurg Psychiatry 88:756–760. https://doi.org/10.1136/jnnp-2017-315878CrossRefPubMed

43.

Shahrizaila N, Lehmann HC, Kuwabara S (2021) Guillain-Barré syndrome. Lancet. https://doi.org/10.1016/S0140-6736(21)00517-1. Epub ahead of print. PMID: 33647239CrossRefPubMed

44.

Siddiqui AK, Huberfeld SI, Weidenheim KM et al (2007) Hydroxychloroquine-induced toxic myopathy causing respiratory failure. Chest 131:588–590. https://doi.org/10.1378/chest.06-1146CrossRefPubMed

45.

Singh S, Govindarajan R (2020) COVID-19 and generalized myasthenia Gravis exacerbation: a case report. Clin Neurol Neurosurg 196:106045. https://doi.org/10.1016/j.clineuro.2020.106045CrossRefPubMedPubMedCentral

46.

Stein M, Bell MJ, Ang LC (2000) Hydroxychloroquine neuromyotoxicity. J Rheumatol 27:2927–2931PubMed

47.

Stenner M, Vent J, Hüttenbrink K‑B et al (2008) Topical therapy in anosmia: relevance of steroid-responsiveness. Laryngoscope 118:1681–1686. https://doi.org/10.1097/MLG.0b013e31817c1368CrossRefPubMed

48.

Svačina MKR, Kohle F, Sprenger A, Lehmann HC (2021) Could symptom overlap of COVID-19 and Guillain-Barré syndrome mask an epidemiological association? J Neurol 17:1–3. https://doi.org/10.1007/s00415-021-10515-8. Epub ahead of print. PMID: 33730264; PMCID: PMC7966909CrossRefPubMedPubMedCentral

49.

Tam CC, O’Brien SJ, Petersen I et al (2007) Guillain-Barré syndrome and preceding infection with campylobacter, influenza and Epstein-Barr virus in the general practice research database. Plos One 2:e344. https://doi.org/10.1371/journal.pone.0000344CrossRefPubMedPubMedCentral

50.

Tisdale AK, Chwalisz BK (2020) Neuro-ophthalmic manifestations of coronavirus disease 19. Curr Opin Ophthalmol 31:489–494. https://doi.org/10.1097/ICU.0000000000000707CrossRefPubMed

51.

Tsivgoulis G, Fragkou PC, Lachanis S et al (2020) Olfactory bulb and mucosa abnormalities in persistent COVID-19 induced anosmia: a magnetic resonance imaging study. Eur J Neurol. https://doi.org/10.1111/ene.14537CrossRefPubMed

52.

Vaira LA, Hopkins C, Petrocelli M et al (2020) Do olfactory and gustatory psychophysical scores have prognostic value in COVID-19 patients? A prospective study of 106 patients. J Otolaryngol Head Neck Surg 49:56. https://doi.org/10.1186/s40463-020-00449-yCrossRefPubMedPubMedCentral

53.

Zhang AJ, Lee AC‑Y, Chu H et al (2020) SARS-CoV‑2 infects and damages the mature and immature olfactory sensory neurons of hamsters. Clin Infect Dis. https://doi.org/10.1093/cid/ciaa995CrossRefPubMedPubMedCentral

54.

Zhou F, Yu T, Du R et al (2020) Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 395:1054–1062. https://doi.org/10.1016/S0140-6736(20)30566-3CrossRefPubMedPubMedCentral

Titel: Neuromuskuläre Komplikationen einer SARS-CoV-2-Infektion – Teil 1: periphere Nerven
verfasst von: Prof. Dr. Helmar C. Lehmann
Benedikt Schoser
Gilbert Wunderlich
Peter Berlit
Gereon R. Fink
Publikationsdatum: 26.03.2021
Verlag: Springer Medizin
Schlagwörter: Krankheiten des peripheren Nervensystems
COVID-19
SARS-CoV-2
Guillain-Barré-Syndrom
ICU-Acquired Weakness
Anosmie
Erschienen in: Der Nervenarzt / Ausgabe 6/2021
Print ISSN: 0028-2804
Elektronische ISSN: 1433-0407
DOI: https://doi.org/10.1007/s00115-021-01094-0

Passend zum Thema

Nervengesundheit

Regeneration peripherer Nerven ist möglich

Während sich Nervenzellen des zentralen Nervensystems nach Schädigungen kaum wieder erholen, können sich periphere Nerven nach Verletzungen oder Kompressionen regenerieren. Neurotrope Nährstoffe wie Uridinmonophosphat und B-Vitamine können den Regenerationsprozess geschädigter Nervenfasern unterstützen.

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2021

COVID-19 in Neurologie und Psychiatrie

Neurovaskuläre Manifestationen von COVID‑19 – aktuelle Studienlage

Versorgung von Parkinson-Patienten in Deutschland: Status quo und Perspektiven im Spiegel des digitalen Wandels

Mitteilungen der DGPPN 7/2021

Mitteilungen der DGN

Menschen mit Schizophrenie, Demenz und Abhängigkeitserkrankungen in Zeiten von Corona

Passend zum Thema

Regeneration peripherer Nerven ist möglich